AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has entered into an agreement with Biogen Idec (NASDAQ: BIIB) - a U.S. based Biopharma company - to identify a potential companion diagnostic test that may be used to select patients likely to respond to a Biogen Idec therapeutic candidate in clinical development.
